Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy

You may also be interested in...

Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next

Atorvastatin launch “reinforced the belief in the Indian generic companies,” Sawhney says. Approval of anti-malarial Synriam, the first novel drug developed in India, will lead to “belief that we from India can also develop new products.”

Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals – An Exclusive Interview With PharmAsia News (Part 1 of 2)

In His First Media Interview Ranbaxy CEO Arun Sawhney Discusses U.S. FDA Saga And Atorvastatin Launch

Uncharacteristically, the reticent and seasoned CEO opened up on a host of untold stories at Ranbaxy

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts